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The CBAJN mouse, a mutant of CBA/H, carries an X-linked recessive defect, 
reflected in part by its inability to respond to Type III pneumococcal polysaccha- 
ride, a  ~thymus-independent antigen" (1). This defect has been studied exten- 
sively by Scher and his colleagues (2-10), who have confirmed that the defective 
gene is X linked and recessive and have also shown that the defective  phenotype 
is expressed in B lymphocytes. This defective phenotype is associated with two 
major abnormalities of immune function: (a) inability to produce significant 
antibody responses to certain thymus-independent antigens (1, 2, 5, 9) and (b) 
failure to produce at least some sets of high affinity antibodies after immuniza- 
tion with sheep erythrocytes (11). 
Since all CBA/N T-cell responses which have been examined are normal (3), 
and there is no evidence that abnormal suppressor T-cell activity accounts for 
these defective B-cell responses (2), it has been suggested that these abnormal 
immune  responses  reflect a  B-cell  maturation  defect  (10). Analyses of the 
surface properties of CBA/N B cells have indicated that CBAfN B cells (a) fail to 
develop M-locus determinants (10), (b) express abnormally low concentrations 
of surface C3  receptors (10),  (c) lack B  cells which bear low to intermediate 
amounts of immunoglobulin on their surfaces (6, 7), and (d) have an increased 
ratio of IgM to IgD chains on their cell membranes (8).  Thus CBA/N B  cells 
have surface and functional characteristics of immature B cells. 
These considerations suggest that CBA/N mice may lack a mature subclass of 
B cells which expresses characteristic surface structures, analogous to surface 
Ly  ÷ components which are selectively expressed on distinct T-cell subclasses 
(12). To test this possibility, we have immunized CBA/N F, mice carrying the 
defective X  chromosome with normal parental  spleen cells in an attempt to 
serologically define this B-cell subclass. The resulting antiserum defines a cell 
surface component expressed selectively on approximately 50% of H cells. This 
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surface  component  is  directly  involved  in  triggering  of  B  cells 
antibody. 
11 
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Materials and Methods 
Animals.  C57BL/6  (B6), 1 BALB/c, A/J,  DBA/1, and CBAdHT6  (CT6) mice, 8-10 wk of age, 
were obtained from The Jackson Laboratory,  Bar Harbor, Maine. CBA/N mice were originally 
obtained from the NIH and maintained at Yale by R. K. Gershon. CBA/N ~ mice were mated with 
BALB/c dto produce normal F1  Q and defective F1  ~hybrid offspring. 
Preparation of Lymphocyte Subpopulations.  Whole spleen cell suspensions were prepared by 
teasing the spleen with forceps in a Petri dish containing phosphate-buffered saline plus 5% fetal 
calf serum and then flushing the suspension through a nylon gauze. Macrophage-depleted spleen 
cells were prepared by incubating spleen cells with carbonyl-iron on a rotator at 37°C for 1/2 h; the 
cells were then settled on a  magnet and the supernatant cells removed. Purified T lymphocytes 
were obtained from nylon wool columns, according to the method used by Julius et al. (13); 80-90% 
of the recovered cells were Thyl  + and 5-10% were Ig  +. Non-T cells were obtained by treating spleen 
cells twice with anti-Thyl plus complement (C).  Highly purified B  cells were also obtained by 
elution of spleen cells from a Rabbit anti(a)-mouse-Fab coated Sephadex G-200 column (14); these 
cells were 96-99% Ig  + by immunofluorescent criteria. 
Analysis of  Binding Activity ofSera.  2.5 x  106 lymphocytes were incubated with 50 ftl of test or 
control sera at various dilutions for 1/2 h  at 4°C in the presence of 0.2% Na azide. After washing 
three times,  the cells were  then incubated with a  fluorescein-conjugated goat  a-mouse  mIgG 
(GaMIgG) kindly provided by Dr.  L.  A.  Herzenberg,  Stanford Medical School, Stanford,  Calif. 
Background levels of spleen cell fluorescence,  as indicated by the numbers of fluorescent cells 
treated with control serum, followed by fluorescein isothiocyanate (FITC) GaMIgG, were less than 
3%. All sera were ultracentrifuged at 40,000 rpm for 20 min to remove aggregated material. 
Analysis of  Functional Activity of Test and Control Sera.  Mice were immunized intravenously 
(i.v.) with sheep erythrocytes (SRBC) or horse erythrocytes (HRBC) alone or in combination with 
varying dilutions of test or control serum; 4-8 days later the mice were killed and the number of 
spleen plaque-forming cells (PFC) to sRBC or HRBC was determined in a  modified Cunningham 
assay (15).  In some experiments, '<B" mice, i.e. thymectomized, lethally irradiated mice restored 
with T-cell-deficient bone marrow (for details see reference 15), were immunized with SRBC and 
test or control sera. 
Results 
I.  Production of Antiserum.  Since the defective X-linked gene is recessive, 
we immunized defective  (CBA/N  Q  ×  BALB/c d) F~ ~  and normal (CBAJN  × 
BALB/c)  F1  ~  mice with BALB/c  spleen cells to produce a  test and a  control 
serum,  respectively.  Immunization  was achieved by an initial  intraperitoneal 
(i.p.) injection of 107 BALB/c spleen cells along with 6 ×  109 pertussis organisms 
followed by weekly injections with progressively  increasing numbers of spleen 
cells in increments of 107/wk.  After 5 wk, the ~  and  Q F1 animals were bled to 
produce a  test and control serum,  respectively.  The test antiserum was called 
aLyb3 for reasons discussed below, and see reference 16. 
To  determine  the  Ig  class  of the  functional  antibody,  the  antiserum  was 
treated with 2-mercaptoethanol  (0.1  M  2-mercaptoethanol  in a  ratio  1:1) and 
alkylated  with  iodoacetamide  (0.1  M  ICH2  CONH2  in  a  ratio  1:1).  Neither 
binding activity nor functional activity of the test serum were eliminated after 
this treatment.  Absorption of the antiserum with various lymphocyte pepula- 
~Abbreviations  used in this paper:  a,  anti; BM,  bone marrow;  B6,  C57BL/6; CT6, CBA/HT6; 
FITC, fluorescein isothiocyanate; GaMIgG,  goat a-mouse IgG; HRBC,  horse erythrocytes; PFC, 
plaque-forming cells; TNP, trinitrophenyl. 12  DEFINITION  OF  A  B-CELL  SURFACE  TRIGGERING  STRUCTURE 
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FIG.  1.  Titration  of  ~Lyb3  on  BALB/c spleen  cells.  Fluorescent  profiles  and  percent 
specific fluorescent staining of BALB/c spleen cells, incubated  with various dilutions of 
aLyb3 or control serum followed by labeling with FITC-GaMIgG, are shown.  (---),  aLyb3 
serum; (-), control serum. 
tions was performed at 4°C for 1 h at a concentration of 50-100  x  106 cells/40 ~l 
serum. 
H. Analysis of Reactivity  of the Test and Control Sera 
(a) DOSE RESPONSE OF ANTISERA (FIG.  1).  No cytotoxicity was apparent after 
spleen cells from BALB/c mice were exposed to different concentrations of the 
test antiserum in the presence of a highly active rabbit C. To determine whether 
the serum specifically reacted with BALB/c cells but did not fix C, spleen cells 
were incubated with varying dilutions of test or control serum and then labeled 
with FITC-GaMIgG (which reacts directly with <2% of B cells). This approach 
demonstrated that the test serum reacted with approximately 20-30%  of the 
spleen cells in dilutions as high as  1:40, compared with control serum which 
was completely unreactive. Therefore, in the following experiments, the test 
and control sera were used at a final dilution of 1:20. 
(b)  REACTIVITY OF TEST  AND  CONTROL SERUM  AGAINST DIFFERENT LYMPHOID 
SUBPOPULATIONS (TABLE IA).  The test serum but not the control serum reacted 
with approximately 30% of whole spleen and macrophage-depleted spleen cells, 
46%  of purified  B  cells  and  0-4%  of bone  marrow  (BM)  cells;  T  cells  and 
thymocytes were  completely negative.  Further  Fluorescence  Activated  Cell 
Sorter analysis showed that the fluorescent cells were found mainly within the 
smaller B lymphocytes (results not shown). Since these data indicate that the 
(CBA/N  ×  BALB/c) F1  d  aBALB/c spleen  serum  reacts  selectively with a 
portion of B cells, and does not react with T cells (or nonlymphoid cells, results 
not  shown),  we  have provisionally termed the  antiserum aLyb3 for ease  of 
discussion, although we do not yet know whether this serum defines a  single 
discrete component on this B-cell subclass. 
(c) ONTOGENY OF Lyb3 CELLS (TABLE I B). Reactivity of  the ~Lyb3 serum against 
spleen cells from B6 mice of different ages was determined. No reactivity was 
noted against cells from newborn mice; at 18 days 19% of the cells were Lyb3  + 
while maximum reactivity (30%) was noted using spleen cells from mice 110 
days of age. 
I 
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TABLE  I 
Characterization of Lyb3 + Cells 
A.  %Lyb3  + cells in different BALB/c lymphocyte populations 
Cell population  % Lyb3  +* 
13 
Unseparated spleen cells  30 
Macrophage-depleted spleen cells  30 
B cells  46 
BM cells  2 
Thymus cells  0 
T cells  0 
B.  Ontogeny of Lyb3 surface component 
Age of spleen cell donor (days)  % Lyb3  ÷* 
2  9 
18  19 
56  30 
110  33 
C.  Strain distribution of Lyb3 surface antigen 
Strain  H-2 haplotype  % Lyb3  +* 
CBA/N  k  0 
CBA/T6  k  25 
BALB/c  d  30 
B6  b  30 
A/J  a  25 
DBA/1  q  25 
* Each figure represents the mean of three to six individual mice per 
group. SE of the mean was less than 10% for all groups. 
(d) REACTIVITY OF ~Lyb3 SERUM  AGAINST SPLEEN  CELLS OF DIFFERENT  STRAINS 
(TABLE  IC).  We  compared the proportion of Lyb3  + spleen cells obtained from 
B6,  BALB/c,  CT6,  DBA/1,  and A/J and  CBA/N mice.  B6 and BALB/c spleen 
populations contained 30% Lyb3  ÷ cells; CT6,  DBA/1, and A/J mice about 25%; 
and CBA/N 0-5%. The reactivity of ~Lyb3 against spleen cells from CBA/N mice 
(5%) was reduced to undetectable levels by preincubating the cells with aggre- 
gated normal mouse serum to block Fc receptor binding; such pretreatment had 
no  influence  on  the  reactivity  of aLyb3  serum  with  spleen  cells from  other 
strains. 
III. Ability of oLLyb3 Serum to Trigger B Cells to Produce Specific Antibody 
after In Vivo Immunization  with Low Doses of Antigen 
(a)  ~Lyb3  ENHANCEMENT  OF  PFC  RESPONSES  OF  NONMUTANT,  Lyb3  +  MOUSE 
STRAINS.  To  determine  whether  the  reaction  of this  serum  with  the  Lyb3 
component(s) on the surface of B  cells altered the immune reactivity of these 
cells, we examined the PFC response of BALB/c mice injected 4 days previously 
with 5 × 105 SRBC alone or in combination with graded doses of aLyb3 or control 
serum.  Mice injected with SRBC alone or in combination with graded doses of 
control  serum  produced  about  500  PFC  per  spleen  (5-15  PFC  per  108  cells), 
whereas mice injected with SRBC and optimal concentrations of aLyb3 serum 14  DEFINITION  OF  A  B-CELL  SURFACE  TRIGGERING  STRUCTURE 
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FIG.  2,  In vivo dose response of aLyb3 serum. BALB/c mice were injected i.v. with 5  ×  10  5 
SRBC plus varying doses of aLyb3 or control serum and their anti-SRBC response measured 
on  day  4.  Each  point  represents  the  mean  PFC  response  of four  to  six  mice  from  a 
representative experiment of a  series of four. 
produced 15 to 20-fold more anti-SRBC PFC (Fig. 2). Injection of higher doses of 
antiserum  resulted  in progressively decreasing responses,  probably reflecting 
either an opsonization effect or the presence of excessive amounts of aLyb3 on 
the surface of B cells. Similar enhancement of aSRBC responses of CT6 and B6 
mice were also observed. In contrast,  i.v. injections of varying doses of aLyb3 
serum failed to enhance the anti-SRBC PFC response of CBA/N mice, indicating 
that the enhancement effect was clearly due to a  specific reaction of the serum 
with a component which is absent in the CBA/N mice (Fig. 3). Finally, studies of 
the time-course  of this  enhanced  PFC  response  also indicated  that the peak 
response occurred on day 6,  and by day 8 the response had declined to normal 
levels (Fig. 3). 
(b)  ~Lyb3  ENHANCEMENT IS ANTIGEN SPECIFIC (TABLE II).  Mice injected with 
aLyb3  serum  without  antigen  did  not  produce  significant  PFC  responses to 
either  SRBC  or  HRBC.  In  addition,  the  enhanced  PFC  response  of mice 
immunized with low doses of either SRBC or HRBC plus ~Lyb3 was specific for 
the immunogen. These findings indicate that aLyb3 serum acts synergistically 
with antigen to produce enhanced antigen-specific PFC responses. 
(c)  ABSORPTION  OF ENHANCING ACTIVITY OF O~Lyb3  SERUM BY DIFFERENT LYM- 
PHOCYTE POPULATIONS  (TABLE III).  Absorption of ~Lyb3 with purified B6 B cells 
eliminated subsequent in vivo enhancing activity, whereas absorption of ~Lyb3 
with thymocytes, purified T cells, or BM cells did not.  These findings  (a) con- 
firm the conclusion of section II b, that aLyb3 serum reacts selectively with B 
cells and (b) indicate in addition that the enhancing effects of the serum reflect a B.  HUBER,  R.  K.  GERSHON,  AND  H.  CANTOR  15 
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Fro.  3.  Time-course and specificity control of the enhanced PFC response. CT6 and CBA/ 
N mice were injected with 5 x  l0  s SRBC plus 20 ~l aLyb3 or control serum and their anti- 
SRBC PFC response was measured on days 4, 6, and 8. Each point represents the mean PFC 
response of two to three mice. 
TABLE  II 
Antigen Specificity of a.Lyb3-Induced B-Cell Activation 
Dose of immu-  aLyb3 sera 
nizing antigen  (20 ~tl) 
SRBC PFC/  HRBC PFC/ 
spleen*  spleen* 
Direct  Indirect  Direct  Indirect 
No antigen  +  0  0  0  0 
5  ×  105 SRBC  +  21,450  19,500  65  0 
5 x  105 HRBC  +  390  390  18,070  16,900 
* Anti-SRBC and anti-HRBC PFC responses, 4 days after i.v. immuni- 
zation with the indicated dose of RBC. Mean response of three mice 
per group. 
direct interaction between aLyb3 and a component on the surface of B cells. 
Analysis of the Role of  Lyb3 in Antigen-Dependent B-Cell Triggering.  The 
data  presented in  section IH  suggest  that  stimulation  of the  Lyb3  surface 
component on antigen-reactive B cells allows more efficient triggering of these 
cells by antigen. This implies that the CBAJN mouse, which lacks Lyb3 + B cells, 
might be expected to respond poorly to relatively low doses of  antigen. We there- 
fore compared the PFC responses of CBAJN mice and CT6 age- and sex-matched 
mice (the latter are identical to the CBA/N  as judged by indefinite mutual 
acceptance of skin grafts,  B.  Huber,  unpublished observation).  CBA/N mice 
were unable to produce significant PFC  responses to relatively low doses of 
antigen, in contrast to CT6 (Fig. 4 A). 
To test the notion that the enhancing effects of aLyb3 serum upon the PFC 
response of the normal strain (CT6) would be particularly decisive when the 16  DEFINITION  OF  A  B-CELL  SURFACE  TRIGGERING  STRUCTURE 
TABLE  III 
Removal of aLyb3 Enhancing Activity by Absorption of Sera 
with B Cells But Not Thymocytes or T Cells* 
aLyb3 antise-  Cell population  Direct anti-SRBC PFC (mean 
rum  used for absorption  +  range of three experiments) 
td 
-  -  423 (260-535) 
20  -  8,320 (6,240-9,620) 
20  Thymus  6,825 (6,110-7,540) 
20  T  5,590 (5,200-5,980) 
20  BM  5,135 (3,380-6,890) 
20  B  875 (260-1,690) 
*  40 ~zl antiserum were absorbed on ice with 10  s cells for 1 h. 
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Fla. 4.  PFC response of CBA/N and CT6 mice to gradually increasing doses of SRBC. The 
total (developed) PFC responses of CBA/N (O) and CT6  (Q) 7 days after i.v. injection of 
increasing doses of SRBC. Each point represents the mean response of two to four mice. (B) 
Enhancing activity of aLyb3 in combination with gradually increasing doses of SRBC  in 
CT6 mice. Total (developed) PFC responses of CT6 mice 6 days after i.v. administration of 20 
/zl of aLyb3 (0) or control serum (O) in combination with increasing doses of SRBC. Each 
point represents the mean response of two to four mice. 
signal  provided  by  antigen  and  T  cells  is  relatively  low,  we  examined  the 
enhancing  effects of aLyb3  in  the  presence  of (a)  different  concentrations  of 
antigen  and  (b) in the presence of limiting numbers  of T  cells. 
The administration  of aLyb3 serum  markedly  enhanced  the reponse  of CT6 
mice to low doses of SRBC  (Fig. 4 B). By contrast, the response of these mice to 
large  doses of SRBC  was  not  significantly enhanced  by the  administration  of 
aLyb3  serum.  These findings are consistent with the  idea that  increased  eft]- B.  HUBER~  R.  K.  GERSHON,  AND  H.  CANTOR 
TABLE  IV 
The Effect of a.Lyb3 on B cells in the Absence of  Detectable T-Cell 
Function 
A.  Primary aSRBC PFC responses in "B" mice* 
Direct PFC/spleen 
Immunization 
(no. SRBC  x  106) 
0.5 
3 
10 
100 
Control serum 
(range)  aLyb3 (range) 
0  0 
0  520 (500-560) 
0  675 (630-720) 
90 (0-180)  1,680(960-2,400) 
17 
B.  Secondary aSRBC responses of SRBC-primed B cells in lethally 
irradiated syngeneic hosts$ 
Indirect PFC/spleen 
Recipient chal- 
lenge SRBC  Control serum 
(range)  aLyb3 (range) 
None  0  0  (30) 
107 SRBC  150 (120-180)  1,560 (1,240-1,980) 
* Mean PFC response of "B" mice (see Materials and Methods) 6 days 
after i.v. injection of 20 ~l of control or aLyb3 serum +  SRBC; three 
mice per group. 
$ Mean PFC response of irradiated (850 R) hosts given 12 ×  106 "B" cells 
(obtained  after  aThyl  +  C  treatment  of spleen  cells) from donors 
primed 4 mo previously with 107 SRBC plus aLyb3 or control serum. 
Mean PFC response of four mice per group on day 4 is shown. 
ciency of  the antibody response in the presence of aLyb3 serum is most apparent 
when the antigen-induced signal is suboptimal. 
The ability of aLyb3 to substitute for T-helper activity in the induction of a 
primary and  secondary response was also tested.  B  mice  (see Materials  and 
Methods) did not produce significant aSRBC after priming with up to 10  s SRBC 
plus control serum; the administration of aLyb3 to these mice resulted in the 
production of a significant PFC response (Table IV A). 
Moreover,  B  cells from antigen-primed  donors could adoptively transfer  a 
secondary antibody response to lethally irradiated hosts only if co-transferred 
with Lyb3 plus antigen (Table IV B). No response was seen if the primed B cells 
were transferred with antigen alone or with aLyb3 alone. 
Discussion 
The studies of Scher and his co-workers have indicated a  B-cell maturation 
defect in CBA/N mice (see introduction). Our work confirms and extends these 
findings. We have shown that serum produced by immunization of defective F~ 
mice with nondefective parental cells reacts predominantly with a subclass of B 
cells from mice of many H-2 genotypes. Although a possible additional reaction 
with  macrophages  has  not  been  ruled  out,  the  serum  does  not  react  with 
thymocytes or T  cells  (and  cannot be absorbed by brain  cells,  liver cells,  or 18  DEFINITION  OF  A  B-CELL  SURFACE  TRIGGERING  STRUCTURE 
kidney  cells,  data  not  shown).  Since  this  antiserum,  provisionally  termed 
aLyb3, does not react with BM cells and reacts only weakly with splenic B cells 
from young mice,  it  is  likely  that  it  defines  a  cell  surface  differentiation 
component(s) expressed selectively on mature B cells. 
In view of Lyb3 expression on the surface of B  cells from all mouse strains 
tested, it is likely that this component is specified by genes expressed during the 
differentiation of B cells of all mouse strains. The present studies do not indicate 
the location of the structural gene(s) coding for this component and, since it is 
likely that the present method of immunization has defined a constant portion 
of this structure, these data do not bear upon whether Lyb3 is expressed as 
different alleles in different mouse strains. 
The reaction of aLyb3 with B  cells from all strains tested (except CBA/N) 
markedly enhanced the development of antigen-specific PFC in the presence of 
suboptimal doses of antigen. This enhancement reflected a  direct interaction 
between Lyb3  antiserum  and  a  component on  the  surface of B  cells,  since 
enhancing activity was removed by absorption of the serum with B cells, but not 
T cells, thymocytes, or BM cells. Enhancement is very likely due to stimulation 
of Lyb3  + B cells, rather than removal of"suppressive" B cells by opsonization, in 
view of (a) the loss of enhancement with increasing doses of aLyb3 and (b) the 
finding that similar enhancing effects can be produced in vitro (data not shown). 
Since, (a) Lyb3 antiserum does not induce a '~polyclonal" PFC response when 
administered without antigen, and (b) the enhancement of antibody produced 
is specific for the immunizing antigen, it is likely that it interacts with a B-cell 
surface structure that is directly involved in antigen-dependent B-cell triggering. 
Possibly this surface component(s) normally acts to increase the efficiency of 
specific B-cell triggering by antigen and/or T-cell factors.  This possibility  is 
illustrated most directly by the finding that the CBA/N mutant, lacking Lyb3  + 
B cells, fails to respond to doses of antigen that elicit substantial responses in 
the nonmutant CBA/HT6 strain. 
Lyb3 may represent the ~'constant portion" of the B-cell antigen receptor or 
may be distinct from the Ig antigen receptor. Since,  (a) the administration of 
aLyb3 serum can partially replace the requirement for T cells in both primary 
and secondary responses to a  thymus-dependent antigen (see Results,  section 
IV), (b) CBA/N mice do not generate normal profiles of T-cell-dependent high 
affinity antibodies after immunization with SRBC (11), and (c) the aLyb3 serum 
described here has no anti-T-cell activity (see Results, sections IIb and HI c), it 
is  possible  that  this  serum reacts  with  a  previously undefined cell  surface 
component(s) on a subclass of B cells which acts as a receptor for a certain T-cell 
signal(s). This signal would result in more efficient triggering of a portion of B 
cells by antigen, as well as the subsequent generation of high affinity antibody. 
The idea that a  special subclass of mature B  cells is required for the PFC 
response to low concentrations of antigen and for the production of high affinity 
antibody is most clearly suggested from the work of Goidl and Siskind  (17). 
These authors showed that, in the presence of identical numbers of adult T cells 
and in the same adult environment, splenic B cells from mice less than 7 days of 
age do not produce high affinity antibody, whereas B cells from older mice (i.e., 
greater than 10 days of age) do. Their work suggests that between 1 and 2 wk of 
age B cells undergo a maturational event which may allow a portion of B cells to B.  HUBER,  R.  K.  GERSHON,  AND  H.  CANTOR  19 
respond differently  to T-cell signals. This maturational step may be reflected by 
the development of a B-cell subclass expressing the Lyb3 component (which also 
first appears in the 2nd wk of life on B cells of normal animals [see Results, 
section II c]). 
B  cells of CBA/N mice also  do not respond normally to  certain ~'thymus- 
independent" antigens (e.g., trinitrophenyl(TNP)-Ficoll) but do respond to oth- 
ers (e.g., TNP-lipopelysaccharide). The present studies do not directly indicate 
whether cells of the Lyb3  ÷ subclass are responsible for reactivity to the TNP- 
Ficoll category of thymus-independent  antigens. Possibly the defective response 
of CBA/N mice to this category of antigens may reflect an arrest of normal B-cell 
maturation, resulting in an absence of a mature Lyb3 + B-cell subclass which can 
respond without T-cell help to certain thymus-independent antigens. 
Taken together, these considerations suggest that aLyb3 serum may prove 
extremely useful in understanding the molecular basis of B-cell triggering. In 
addition, some practical implications of aLyb3 activity deserve comment. Injec- 
tions of relatively small quantities of this serum along with weakly immuno- 
genic doses of antigen result in a substantial (10- to 20-fold) increase in specific 
antibody formation. It is therefore possible that aLyb3 serum will prove useful 
as  a  potent stimulus of specific  antibody production against relatively weak 
antigens such as Ig idiotypes, minor histocompatibility products, tumor-associ- 
ated determinants, and cell surface differentiation antigens. 
Summary 
CBA/N mice have an X-linked B-cell maturation defect which is reflected in 
part in an absence or dysfunction of a  subclass of mature B cells.  We have 
immunized  the defective d offspring of  the mating (CBA/N  2  x BALB/c d) with 
BALB/c spleen cells. The resulting antiserum (aLyb3) selectively reacts with a 
component on the surface of a portion of B cells from a panel of H-2 different 
mouse strains. Binding of aLyb3 serum to this B-cell subclass results in sub- 
stantial  (10- to 20-fold) enhancement of the antibody response to low doses of 
SRBC.  Both binding and enhancing activity are removed by absorption with B 
cells from B6 and BALB/c, but not CBA/N mice. Absorption of the serum with 
bone marrow cells, T cells, or thymocytes from Lyb3  + strains does not remove 
activity. 
Since the enhanced plaque-forming cell (PFC) responses are specific for the 
immunizing antigen, and since no PFC response is produced by injection of the 
antiserum alone, this enhancement probably reflects a second signal produced 
by  specific  interaction between antibody and  the  surface Lyb3  component. 
Moreover, this signal can partially replace the requirement for T cells in the 
production of antibody to a "thymus-dependent"  antigen. These findings (taken 
in conjunction with the previously described immune defects in CBA/N mice and 
other studies of B-cell maturation) suggest to us that Lyb3 is a cell surface com- 
ponent expressed selectively on a  mature B-cell  subclass.  This component is 
important in B-cell triggering by antigen and fails to develop in CBA/N mice, 
due to a dysfunction of a regulatory gene on the CBA/N X chromosome. 
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